Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HW091077 in Refractory Chronic Cough or Unexplained Chronic Cough
NCT07483489Phase 2Not yet recruiting
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute
- Start
- May 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of HW091077 in refractory chronic cough (RCC) and unexplained chronic cough (3 arms), sponsored by Hubei Bio-Pharmaceutical Industrial Technological Institute. Primary endpoint: 24-Hour Cough Frequency at 4 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
HW091077
03
Conditions
refractory chronic cough (RCC)unexplained chronic cough
Beyond the preview
Go deeper on NCT07483489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483489.